Enzon Pharmaceuticals, Inc.
ENZN
$0.0808
-$0.0048-5.61%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.54% | 207.36% | 50.46% | 56.00% | 10.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.54% | 207.36% | 50.46% | 56.00% | 10.38% |
| Operating Income | 3.38% | -207.36% | -50.46% | -56.00% | -2.20% |
| Income Before Tax | -468.57% | -257.32% | -47.75% | -23.68% | 19.15% |
| Income Tax Expenses | -1,150.00% | 1,800.00% | 217.67% | -35.53% | -92.31% |
| Earnings from Continuing Operations | -458.70% | -263.75% | -110.71% | -20.87% | 50.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -458.70% | -263.75% | -110.71% | -20.87% | 50.82% |
| EBIT | 3.38% | -207.36% | -50.46% | -56.00% | -2.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -502.94% | -407.14% | -75.19% | -32.14% | 27.66% |
| Normalized Basic EPS | -33.33% | -259.26% | -47.22% | -21.21% | 20.00% |
| EPS Diluted | -502.94% | -407.14% | -70.80% | -32.14% | 27.66% |
| Normalized Diluted EPS | -33.33% | -259.26% | -47.22% | -21.21% | 20.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -1.61% | -- | -- | -- |